News Focus
News Focus
Followers 21
Posts 1793
Boards Moderated 0
Alias Born 02/03/2006

Re: in2lite post# 38

Tuesday, 03/14/2006 4:58:46 PM

Tuesday, March 14, 2006 4:58:46 PM

Post# of 1303
ok folks, here's some unsolicited DD.

apparently, MMAM (intends) is acquiring Biometis; which is a JV between Sigma Global Corporation and Stason Pharmaceuticals, Inc., see PR copy below.

Attached is Sigma's most recent consolidated financials for 12.31.05:

https://www.otcstockinfo.com/repository/654186/654186_FR10.pdf

The office/call center is down the street from my office and I plan to pay them a visit and report back.

This could be are real find. I like it so far...

IMO, the demand from the anti-aging/stay beautiful market will only grow exponentially; though the organization and delivery of the "clinics" to provide those services is not without start-up, branding and associated development costs (mostly contractual I assume, as I doubt they intend to buy out select physician practices [mostly real estate assets] per se); so the immediate opportunity is movement of retail products throught their pipleline to major players like CVS and Walmart.

That revenue alone should float the boat for the more ambitious presence in the medical maker over market, IMO.

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
10.05.05
PLANO, Texas -- Sigma Global Corporation (Pink Sheets:SGGC), a leading direct-to-consumer provider of medical devices and pharmaceuticals today announced that it has launched Biometis, a medical device and pharmaceutical joint venture with Stason Pharmaceuticals, Inc. Biometis is a Texas corporation with operations in both California and Texas. Biometis intends to introduce its own line of medical devices and generic pharmaceuticals aimed at patients with chronic diseases to retailers, institutions and consumer-direct outlets nationwide. Biometis is limited to new medical devices and generic pharmaceuticals jointly developed by the venture.

"The formation of Biometis provides the resources and capabilities necessary to capture market share in the burgeoning medical device and generic pharmaceutical markets," stated Bryan Chance, Chairman and Chief Executive Officer of Sigma Global Corporation.


In2

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today